TY - JOUR T1 - Acquisition and carriage dynamics of fluoroquinolone resistant Enterobacteriaceae at individual and household levels JF - medRxiv DO - 10.1101/2020.10.29.20222364 SP - 2020.10.29.20222364 AU - Patrick Musicha AU - Andrew J. Stewardson AU - Yin Mo AU - Jascha Vervoort AU - Niels Adriaenssens AU - Samuel Coenen AU - Maciek Godycki-Cwirko AU - Anna Kowalczyk AU - Christine Lammens AU - Surbhi Malhotra-Kumar AU - Herman Goossens AU - Stephan Harbarth AU - Ben S. Cooper Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/11/03/2020.10.29.20222364.abstract N2 - Carriage dynamics of drug-resistant bacteria, especially within households, are poorly understood. This limits the ability to develop effective interventions for controlling the spread of antimicrobial resistance in the community. Two groups consisting of: (i) patients with urinary tract infection requiring antimicrobial treatment; and (ii) patients who were not prescribed antimicrobial treatment were prospectively recruited at three European sites: Antwerp (Belgium), Geneva (Switzerland) and Lodz (Poland). Each index patient and up to three additional household members provided faecal samples at baseline, completion of antimicrobial therapy (or 7-10 days after the first sample for the non-exposed) and 28 days after the second sample. We analysed household-level and individual-level fluoroquinolone resistant Enterobacteriaceae (FQR-E) acquisition and carriage data using Bayesian multi-state Markov models. At the individual level, we estimated a median baseline FQR-E acquisition rate of 0.006 (95%CrI = [0.004, 0.01]) per day, and a median duration of carriage of 24.4 days (95% CrI=[15.23,41.38]). Nitrofurantoin exposure was associated with a reduced rate of FQR-E acquisition (HR=0.28, 95%CrI=[0.14,0.56]), while fluoroquinolone exposure had no clear association with rates of FQR-E acquisition (HR=1.43, 95% CrI=[0.81,2.53]) at individual level. There was evidence that rates of FQR-E acquisition varied by site, and coming from Lodz was associated with a higher acquisition rate (HR=3.56, 95% CrI=[1.92, 6.34]). Prolonged duration of carriage was associated with exposure to fluoroquinolone or nitrofurantoin during the study, use of any antimicrobial agent in the prior 12 months and travel to endemic regions. At household level, we found strong evidence of positive association between FQR-E acquisition and fluoroquinolone exposure (HR=3.43, 95% CrI=[1.51,7.74]). There was weak evidence of negative association between FQR-E acquisition and nitrofurantoin exposure (HR=0.42, 95%CrI=[0.12, 1.24]. Similar to the individual level, carriage duration was also associated with antimicrobial exposure at the household level. Our study has identified within household contacts as an important route for FQR-E transmission and highlights the need for prioritising household focused interventions to control FQR-E spread.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe original SATURN cohort study was supported by the European Commission under the 7th Framework Programme (FP7-HEALTH-2009-SINGLE STAGE-SATURN, contract 241796); and by the Methusalem grant of the Flemish government to Herman Goossens. PM was sup-ported by the UK Medical Research Council (MRC-UK) JPI-AMR MODERN Project grant (MR/R004536/1) to BSC. AJS is supported by an Australian National Health and Medical Re- search Council Early Career Fellowship (GNT1141398). BSC was supported by the MRC-UK Senior Fellowship Grant (MR/K006924/1)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Geneva University Hospitals (protocol 10-123), Antwerp University Hospital (B30020109056), and Medical University of Lodz (RNN/127/10/KE z 13 lipca 2010 r)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in the manuscript have been summarised and reported within the manuscript. Raw data and code used to analyse the data will be made available online. ER -